A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: Efficient maturation of DCs by co-culture with LAK cells in vitro

YUTARO YANO1*, YUJI UEDA1*, TSUYOHI ITOH1*, NOBUAKI FUJI1, KAORI OKUGAWA1, KEI NAITO1, KENICHIRO IMURA1, JUNJI KOHARA1, TAKASHI HAYASHI2, KAZUKI NAKANE3, YUKO MATSUURA3, KEIICHI KAWAI3 and HISAKAZU YAMAGISHI1

1Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566; 2Department of Surgery, Takeda Hospital, Shiokoji-cho 841-5, Shimogyo-ku, Kyoto 600-8558; 3Bio-health Center, Takeda Hospital, Keiaikosan-Kyoto BLDG, Kankoboko-cho 87, Shimogyo-ku, Kyoto 600-8009, Japan

Received January 27, 2006; Accepted March 20, 2006

Abstract. Among a variety of antigen presenting cells (APCs), accumulating results support that the mature dendritic cell (DC) has the potential to induce efficient cytotoxic T lymphocyte (CTL) responses in the context of peptide-based immunotherapy. DCs have been known to assume the mature form by signaling through the CD40-CD40 ligand (CD40L) interaction, which may be provided by activated CD4+ T cells expressing abundant CD40L molecules on their surfaces. Here, we report that DCs generated from peripheral blood monocytes obtained from patients with advanced cancer exhibit a mature phenotype after co-culturing with autologous lymphokine-activated killer (LAK) cells generated by the stimulation of peripheral blood mononuclear cells with anti-CD3 monoclonal antibody (mAb) and interleukin (IL)-2. Part of this process appeared to be dependent on the expression of CD40L on the surface of LAK cells, although it was also suggested that some other humoral factors produced by LAK cells may be involved in this effect as well. DCs derived from the donors, of which LAK cells demonstrated a higher Th1/Th2 ratio upon activation determined by the intracellular detection of interferon-γ and IL-4, showed more efficient maturation upon co-culture with LAK cells than DCs from donors with a low Th1/Th2 ratio. Importantly, these matured DCs induced a two-times stronger antigen-presenting capacity measured by an allo-reactive mixed lymphocytes reaction assay as compared to immature DCs. These results imply the use of the combination of DCs and LAK cells for immunotherapy against cancer.

Introduction
The dendritic cell (DC) is the most potent antigen-presenting cell (APC) and is used as an adjuvant for a number of clinical studies of active immunotherapy for cancer. Although the DC is considered to be a powerful tool to immunize patients being potentially under an immunosuppressive status caused by cancer, the vaccine protocol needs to be well designed in terms of the cell culture environment and the cell source from which DCs are prepared, as well as the maturation status of DCs to elicit efficient anti-tumor responses. Specifically, DCs that have a myeloid origin, including Langerhans cells as well as interstitial DCs, play a critical role in inducing cellular immune responses as acquired immunity, whereas plasmacytoid DCs are involved more in innate immunity (1). So far, human peripheral blood monocyte-derived myeloid DCs have been most widely used for clinical trials, perhaps because of their accessibility (2). Recently, as a novel way to prepare DCs, macrophages are harvested from human peripheral blood mononuclear cells and differentiated into DCs with the addition of exogenous cytokines in culture (3). However, the more exogenous cytokines are used, the more expensive and labor-intensive the protocol may become. Recently, as a novel way to prepare...
mature DCs without exogenous cytokines, a new strategy utilizing activated T cells by phytohemagglutinin and ionomycin for DC maturation has been proposed by showing that the co-culture of these two types of cells resulted in the maturation of DC in terms of the up-regulation of CD83 expression and the production of IL-12 in the in vitro culture system (8). This strategy was based on evidence that the DC is known to differentiate into the matured form by signaling through a CD40-CD40 ligand (CD40L) interaction, which may be provided by activated CD4+ T cells to have a more potent antigen-presenting capacity (9-11). On the other hand, lymphokine-activated killer (LAK) cells have been studied for use as a modality of tumor immunotherapy for many years. Previous studies have indicated that LAK cells induce an anti-tumor response by perforin-mediated cytolytic activity, as well as the cytokines they produce (12,13). Although these effects are not truly antigen-specific, their applicability for use in immunotherapy remains promising, especially for tumors that lack the expression of MHC-class I molecules on their surfaces.

In this study, we hypothesized that LAK cells induced by anti-CD3 monoclonal antibody (mAb) in the presence of IL-2, which supposedly express abundant CD40L on their surfaces, could stimulate autologous immature DCs and allow them to differentiate into the matured form. We also investigated the capacity of the DCs activated in this protocol as to their ability to present antigens to T cells in an allogeneic mixed lymphocyte response (MLR). To explore the possibility of applying this strategy in a clinical setting, we mostly focused on the experiments using the materials derived from patients with advanced cancer.

Materials and methods

Patients and cells. Peripheral blood mononuclear cells (PBMCs) were isolated from patients with advanced cancer after obtaining written informed consent using Ficoll-Paque PLUS (Amersham-Pharmacia, Uppsala, Sweden) density gradient centrifugation. All patients had received surgery and chemotherapy prior to participation in this study, and at least four weeks had passed at the time of collection of PBMCs. The PBMCs were suspended in 25% human serum albumin (Kaketsuken Inc., Tokyo, Japan) with CP-1 (Kyokuto, Kyoto, Japan) and hydroxyethyl starch at a content of 5x10^7 cells/ml, and divided into vials, each containing 2 ml of the suspension. All vials were stored at -80˚C until use.

In vitro generation of DCs. PBMCs were allowed to adhere in a 6-well plate at a density of 1x10^6 cells/well for 1 h at 37˚C in RPMI-1640 (Nikken, Kyoto, Japan). Adherent cells were then cultured in 4 ml of RPMI-1640 supplemented with 2% heat-inactivated pooled human AB serum, 50 ng/ml of human GM-CSF (PeproTech House, London, UK) and 50 ng/ml of human IL-4 (PeproTech House) for 6 days. Cells were incubated at 37˚C in 5% CO₂.

In vitro generation of LAK cells. PBMCs were seeded in a 24-well plate coated with anti-CD3 mAb at a concentration of 2x10^6 cells/well in 2 ml of RPMI-1640 supplemented with 5% heat-inactivated pooled human AB serum and 100 U/ml of human IL-2 (Shionogi, Osaka, Japan) for 7 days. Cells were incubated at 37˚C in 5% CO₂ and half the medium was changed every 3 days.

Activation of DCs with LAK cells. DCs were co-cultured with LAK cells harvested on day 7 at a ratio of 1:1 (1x10^7 cells in total/well) for 24 h. Cell insert with a pore size of 0.4 μm (NUNC, Rochester, NY) was used in the culture to prevent physical cellular contact in some experiments. For the blocking of CD40-CD40L signaling, LAK cells were pre-incubated with anti-CD40L mAb (TRAP-1, 40 μg/ml, BD Biosciences, Heidelberg, Germany) for 90 min before co-culturing with DCs.

Phenotypic analyses of DCs and LAK cells. Flow cytometric analysis was performed by FACScalibur (Becton-Dickinson, San Diego, CA) using CellQuest software (Becton-Dickinson). DCs were analyzed for the phenotype markers with the following mAbs: anti-CD14, anti-CD40 (Pharmingen, San Diego, CA), anti-CD80, anti-CD83, anti-CD86 (Immunotech, Marceille, France). Monoclonal Abs for CD3, CD4, CD8 and CD40L (Pharmingen) were also used for the phenotypic analysis of LAK cells.

Detection of intracellular cytokine production by LAK cells. For the detection of the intracellular cytokine productions, LAK cells were stimulated with PMA (20 ng/ml) and ionomycin (1 μg/ml) for 4 h in the presence of Golgistop™ (Becton-Dickinson) and treated with Cytofix/CytoPerm™ (Becton-Dickinson), and then were stained with PE-conjugated anti-CD8 and FITC-conjugated anti-interferon (IFN)−γ mAb for 30 min at room temperature. LAK cells producing intracellular IL-4 and IFN-γ were determined by flow cytometry (FACScalibur). All mAbs and isotype-control IgG were purchased from Becton-Dickinson.

T cell proliferation assay. Allo-MLR was performed to evaluate the antigen-presenting capacity of DCs. Responder T cells were used at 6x10^5 cells per well in a 96-well plate. The enrichment of DCs co-cultured with LAK cells was performed using anti-HLA-DR MACS beads (Miltenyi, Bergisch Gladbach, Germany) according to the manufacturer’s instruction. DCs as stimulator cells were added to 2x10^4 cells (stimulator:responder = 1:30) after irradiation (25 Gy) and cultures were set up in triplicate and maintained at 37˚C in 5% CO₂ for 4 days. Cultures were then added 1.0 μCi/well to ³H-thymidine 12 h before harvesting and ³H-thymidine incorporation was measured by scintillation counting.

Results

LAK cells generated from PBMCs derived from patients with advanced cancer express various amounts of CD40L on their surfaces. First, we investigated the surface expression of CD40L on the lymphocytes activated with anti-CD3 mAb in the presence of IL-2. PBMCs derived from patients with several types of advanced cancer including 4 colorectal and 2 lung cancers, as shown in Table I, were put in the culture and activated in vitro, as indicated in Materials and methods. All of the patients enrolled in this study had completed prior
treatment such as surgery and chemotherapy at least four weeks previously. Cells were determined for the surface expression of CD40L by flow cytometric analysis on various days between 1 and 11 after the initiation of the culture. We found that cells reached their maximum level of CD40L expression by day 5 and were able to maintain this expression until day 9 (data not shown) without significant decrease. Therefore, we decided to harvest the LAK cells on day 7 and used them for subsequent experiments as an optimal condition. As shown in Table I, >10% of the LAK cells showed CD40L positivity in three (Donor nos. 1-3) out of six patients. One representative result from FACS analyses demonstrating a considerable amount of CD40L-positive LAK cells is shown in Fig. 1. Most of the cells (86%) that express CD40L were positive for CD4 as well, whereas few of them were positive for CD8 (data not shown). Since we observed substantial variation regarding CD40L expression on LAK cells from donor to donor, several phenotypic characteristics of PBMCs before culture were examined to see if there was any correlation between the levels of CD40L expression and phenotypic markers of PBMCs. Consistent with the finding that CD40L positive cells were mainly observed in the CD4+ T cell population (Fig. 1), patients with a high CD4/CD8 ratio (nos. 1, 2) (>1.0) of PBMCs before culture showed a significantly higher level of CD40L expression (p<0.03, unpaired t-tests) after activation than patients with a low CD4/CD8 ratio (nos. 3-6) (Fig. 2).

**CD40L-positive LAK cells promote phenotypical and functional maturation of DCs in vitro.** Next, we examined if the co-culture with autologous LAK cells promotes the maturation of DCs generated from peripheral blood monocytes. DCs were determined for their expression of CD80, CD83 and CD86 as the maturation markers before and after co-culturing with LAK cells for 24 h. The culture conditions of DCs and LAK cells were determined according to the results from preliminary experiments so that the surface expression of CD86 could become maximum level. The results from donor no. 1 demonstrated that the expression of these maturation markers on DCs was up-regulated after co-culture (Fig. 3a). Interestingly, two patients (nos. 1 and 2, both of whom, showed >20% of CD40L+ cells in LAK cells) out of three with high expression of CD40L showed >50% of CD80+ and CD83+ on DCs after co-culture, whereas all of the patients with low expression of CD40L showed levels of CD83 expression <10% (Fig. 3b). These results support our hypothesis that DCs may be activated

### Table I. Patient characteristics and CD40L expression on lymphokine-activated PBMCs.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/Gender</th>
<th>Cancer type</th>
<th>Metastasis</th>
<th>CD40L expression</th>
<th>Prior therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>56/M</td>
<td>Rectal</td>
<td>Liver metastasis</td>
<td>21.2</td>
<td>S, C</td>
</tr>
<tr>
<td>2</td>
<td>69/M</td>
<td>Lung</td>
<td>Pleural dissemination</td>
<td>24.2</td>
<td>S, C</td>
</tr>
<tr>
<td>3</td>
<td>56/M</td>
<td>Colon</td>
<td>Liver metastasis</td>
<td>10.7</td>
<td>S, C</td>
</tr>
<tr>
<td>4</td>
<td>42/F</td>
<td>Colon</td>
<td>Liver metastasis</td>
<td>1.32</td>
<td>S, C</td>
</tr>
<tr>
<td>5</td>
<td>54/F</td>
<td>Colon</td>
<td>Liver, bone, lung metastasis</td>
<td>0.76</td>
<td>S, C</td>
</tr>
<tr>
<td>6</td>
<td>39/M</td>
<td>Lung</td>
<td>Bone metastasis</td>
<td>0.71</td>
<td>S, C</td>
</tr>
</tbody>
</table>

a% CD40L-positive cells in PBMCs activated with anti-CD3 monoclonal antibody and interleukin-2 in vitro. bS, surgery; C, chemotherapy.
by LAK cells, possibly through the interaction between CD40 and CD40L. To characterize the DCs matured with LAK cells in terms of their function, an allo-MLR experiment was conducted. As shown in Fig. 4, the proliferation of T cells was approximately doubled when DCs matured with LAK cells were used as the APCs as compared to immature DCs. Since there have been some reports showing that DCs that had been cultured with or without LAK cells for 4 days. 1.0 μCi/well of ³H-thymidine was added to the culture before the final 12 h and ³H-thymidine incorporation was measured by scintillation counting to determine T cell proliferation activity. Data obtained from one representative result out of three repeated experiments are shown as an average from triplicated wells (mean ± SD; *p<0.03; **p<0.01).

The maturation of DCs by co-culturing with LAK cells is largely dependent on the interaction between CD40 and
after the co-culture of both cells that mitogen-activated T cells expressing CD40L promoted consistent with a recent report in which Sato used for the stimulation of DCs. Our results seem to be con-

was dependent on the expression of CD40L on LAK cells. Here, we demonstrated that the co-culture of DCs with auto-

Discussion

CD40L. To investigate the significance of CD40L expression on LAK cells on the maturation of DCs, we used a cell insert system to prevent the direct cell-to-cell contact between LAK cells and DCs. As shown in Fig. 6a, the up-regulation of CD83 on DCs was markedly, if not totally, blocked by the use of the cell insert. We then looked into the effect of the signaling specifically through CD40-40L on the maturation of DCs by the incubation of DCs and LAK cells pre-incubated with anti-CD40L mAb to block its signaling (Fig. 6b). The maturation effect on DCs by LAK cells was inhibited by 45 and 64% in patients no. 1 and 2, respectively.

Figure 6. The maturation effects of co-culturing with autologous LAK cells on DCs are abolished by the inhibition of cell-to-cell contact as well as the blocking of CD40-CD40L interaction by monoclonal antibody specific for CD40L. DCs were co-cultured with autologous LAK cells with or without the presence of cell culture insert (a) or the presence of anti-CD40L mAb (b). Percentage of CD83 positive cells in DCs are shown in the figure. The data obtained from one representative result out of three repeated experiments are shown.

and these activated cells efficiently induced DC maturation. In contrast to this report, LAK cells in our culture system expressed at most only 24% of CD40L even after stimulation with anti-CD3 mAb and IL-2 (Table I). This may be attributed to the difference of methods of activation or to the difference of donor populations (healthy vs advanced cancer patients). Nevertheless, substantial amount of CD4+ T cells activated by anti-CD3 mAb and IL-2 expressed CD40L in our setting and contributed to DC maturation.

Importantly, our results indicated that the higher ratio of CD4/CD8 in the PBMCs before culture was associated with a higher frequency of CD40L-positive cells in LAK cells (Fig. 2). This result is consistent with the observation that the CD40L-positive cells predominantly consist of CD4+ T cells (Fig. 1) and, thus, the CD4/CD8 ratio might be helpful to assume responders among the candidate patients with regard to the efficiency of DC maturation before the enrollment into this strategy. Further investigation to address whether this level of expression of CD40L would be good enough to exert DC maturation, leading to the efficient induction of anti-tumor immune responses to treat cancer in vivo is warranted. The ratio of Th1/Th2 of the LAK cells determined by the intracellular productions of IFN-γ and IL-4 also appeared to be important to distinguish the responder from non-responder in terms of the DC maturation efficiency (Fig. 5). In this experiment, although the culture condition for the generation of LAK cells for cytokine assay differs from that for maturation of DCs, previous study suggested that the IFN-γ production between LAK cells induced by a CD3 mAb with IL-2 and those induced by mitogens such as PMA or PHA seems to be similar in terms of cytokine production (19). Indeed, IFN-γ has been reported to induce the differentiation of type-1 polarized DC (DC1), which is more capable of priming CTL by means of enhanced IL-12 production and up-regulation of co-stimulatory signals (14,15), and effective anti-tumor immune responses induced by DC1 have been demonstrated in an animal study (14,16). These studies also implicate the possible use of DC1 for clinical settings in humans. Consistent with these reports, DCs stimulated with LAK cells that specifically produced higher amounts of IFN-γ showed efficient up-regulation of maturation markers (Fig. 5) and the enhanced antigen-presenting capacity (Fig. 4) in the current study. However, this result suggests the importance of humoral factors, including IFN-γ, that exist in the culture and may play an important role for DC maturation besides the signaling through CD40-40L. Indeed, DC maturation was not completely blocked by the use of the cell culture insert to prevent cell-to-cell contact in one of two patients tested (Fig. 6a). Thus, we conclude that the humoral factors may be as important as the cell-to-cell contact with LAK cells in the culture in the current study.

In vivo observation that DCs and NK cells are rapidly recruited to the sites of inflammation supports a concept stating the importance of the link between innate and acquired immunity (17-19). NK cells have been demonstrated to activate DCs and induce their maturation and Th1-type cytokine production mediated by IFN-γ and TNF-α produced by NK cells with a possible involvement of additional factors, such as CD40-40L interaction (20-22). Such DCs (DC1) that are activated by NK cells, have been shown to be resistant to tumor-related suppressive factors and thus induce Th1 and
strong CTL responses. LAK cells are known to contain a considerable amount of CD56 cells, such as NK (CD3/-CD56+), cytolytic NK-T (CD56+CD8+/-CD56+) and cytokine-induced killer (CIK)(CD8+/-CD56+) cells (23). Since the LAK cells in the present study also contained substantial amounts of CD56+ cells (data not shown), although the expression levels varied from donor to donor, it would be interesting to study the detailed phenotypic analysis on LAK cells in terms of the involvement in DC maturation in these conditions.

In conclusion, we have shown that autologous LAK cells induced by anti-CD3 mAb and IL-2 efficiently promote DC maturation in vitro. In vivo experiments using the administration of a mixture of LAK cells and antigen-loaded DCs by intranodal or intratumoral injections to induce anti-tumor immune responses in mouse models are currently underway. Although this strategy requires substantial labor for the preparation not only of DCs but also LAK cells, LAK cells, which can be generated from non-adherent cells derived from PBMCs harvested for the cell source of DCs and would be discarded normally without clinical use, can substitute the addition of recombinant cytokines needed for DC maturation. Thus, this strategy may be taken into consideration for future clinical trials of tumor immunotherapy. However, this strategy needs well-designed culture protocol and condition so that it can comply with good clinical practice (GCP). The efficient selection of patients with an indication for this strategy and CD4/CD8 ratio or Th1/Th2 ratio of the LAK cells may also be necessary.

Acknowledgements

This study was supported in part by a 2004-2005 Grant-In-Aid from the Ministry of Health, Labor and Welfare, Japan (No. 16241801) (to Y.U.) and a 2004-2005 Grant-In-Aid for Scientific Resarch from the Japan Society for the Promotion of Science (No. 90332949) (to N.F.).

References